
2025-03-09
Hāʻawi ʻia ka lāʻau lapaʻau no ka maʻi kanesa e kālele ana i ka hāʻawi ʻana i nā lāʻau lapaʻau kūikawā i nā cell cancer, e hōʻemi ana i ka pōʻino i nā ʻiʻo olakino. Ke hoʻohana nei kēia ala i nā hoʻolālā like ʻole, me nā nanoparticles, antibodies, a me nā peptides cell-penetrating, e hoʻomaikaʻi i ka pono o ka lāʻau lapaʻau a hōʻemi i nā hopena ʻaoʻao, e hāʻawi ana i kahi lāʻau lapaʻau maʻi maʻi maʻi.
Ua ulu nui ka mālama ʻana i ka maʻi maʻi, me ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa e puka mai ana ma ke ʻano he hoʻolālā hoʻohiki. Ke manaʻo nei kēia ala e hāʻawi i nā lāʻau lapaʻau i nā cell cancer, e hoʻonui i nā hopena therapeutic aʻo ka hōʻemi ʻana i ka pōʻino i nā ʻiʻo olakino. ʻAʻole like me ka chemotherapy maʻamau, ka mea e puʻunaue ana i nā lāʻau lapaʻau a puni ke kino, hoʻohana ʻia ka lawe ʻana i nā ʻano hana like ʻole e hoʻopaʻa pono ai i nā cell cancer.
ʻO ka chemotherapy maʻamau ka hopena i nā hopena koʻikoʻi no ka mea e pili ana i nā maʻi maʻi a me nā cell olakino. Hāʻawi ʻia ka lāʻau lapaʻau no ka maʻi kanesa hāʻawi i kahi hoʻonā ma ka hāʻawi ʻana i nā lāʻau lapaʻau i ka pūnaewele tumor. Hoʻemi kēia i ka ʻona ʻōnaehana, hoʻomaikaʻi i ka pono o ka lāʻau, a hiki ke hoʻonui i ka maikaʻi o ke ola o ka maʻi.
Hoʻohana ʻia kekahi mau hoʻolālā hou i ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa, kēlā me kēia me kona pono pono'ī a me nā palena.
ʻO nā nanoparticles nā ʻāpana liʻiliʻi (1-100 nm) i hoʻolālā ʻia e hoʻopili a hāʻawi i nā lāʻau lapaʻau i nā maʻi kanesa. Hiki iā lākou ke hana ʻia e hoʻopaʻa i nā mea loaʻa kikoʻī ma nā pūnaewele maʻi kanesa, e like me EGFR a i ʻole HER2. Hoʻohana mau ʻia nā liposomes, nā nanoparticles polymeric, a me nā nanoparticles inorganic. ʻO ka hopena i hoʻonui ʻia i ka permeability a me ka hoʻopaʻa ʻana (EPR) hiki i nā nanoparticles ke hōʻiliʻili i nā ʻiʻo tumora ma muli o ka leaky vasculature.
Laʻana: ʻO Doxil, kahi liposomal doxorubicin, he lāʻau lapaʻau i hoʻohana ʻia no ka mālama ʻana i ka maʻi ovarian a me ka myeloma lehulehu.
Aia nā ADC i kahi antibody monoclonal i hoʻopili ʻia i kahi lāʻau cytotoxic. Hoʻopaʻa paʻa ka antibody i kahi antigen i hoʻopaʻa ʻia ma nā maʻi kanesa, e alakaʻi ana i ka internalization o ka ADC a me ka hoʻokuʻu ʻana o ka lāʻau i loko o ke kelepona.
Laʻana: Hoʻokumu ʻo Adcetris (brentuximab vedotin) i ka CD30, he pūmua i loaʻa ma kekahi mau pūnaewele lymphoma, e hāʻawi ana i kahi microtubule-disrupting agent.
ʻO nā CPP nā ʻāpana amino acid pōkole e hoʻomaʻamaʻa i ke komo ʻana o nā lāʻau lapaʻau a i ʻole nā nanoparticles i loko o nā cell. Hiki iā lākou ke hoʻohui ʻia i nā mea therapeutic a i ʻole nanoparticles e hoʻomaikaʻi i kā lākou cellular uptake.
Hoʻopili kēia hoʻolālā i ka huli ʻana i nā mea loaʻa i hoʻohālikelike ʻia i nā maʻi kanesa. Hoʻohana ʻia nā ligands a i ʻole nā antibodies e hoʻopaʻa i kēia mau mea loaʻa e hoʻopuka i nā lāʻau lapaʻau a i ʻole nanoparticles ma o ka endocytosis.
Ke komo ikaika nei ka Shandong Baofa Cancer Research Institute i ka noiʻi ʻana a me ka hoʻomohala ʻana i ka moʻolelo ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa ʻōnaehana. Ke nānā nei kā lākou noiʻi ʻana i nā ala pilikino e noʻonoʻo ana i nā ʻano genetic a me nā molecular profiles o kēlā me kēia maʻi, e manaʻo ana e hoʻomaikaʻi i nā hopena lapaʻau a hōʻemi i nā hopena ʻaoʻao.
Hana pū ʻo Shandong Baofa Cancer Research Institute me nā halemai e like me ka Shandong Baofa Cancer Hospital (https://baofahospital.com) e hana i nā hoʻokolohua lapaʻau a unuhi i nā ʻike noiʻi i loko o nā noi kūpono.
Hāʻawi ʻia ka lāʻau lapaʻau no ka maʻi kanesa Hāʻawi ia i kekahi mau mea pono nui ma mua o ka chemotherapy maʻamau:
ʻOiai kāna ʻōlelo hoʻohiki, ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa ke alo nei i kekahi mau pilikia:
He mau ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa ʻae ʻia nā ʻōnaehana i kēia manawa no ka hoʻohana lāʻau lapaʻau:
| Inoa Laau Laau | Kuhikuhi | ʻAno maʻi maʻi maʻi | Kaʻina Hoʻouna |
|---|---|---|---|
| Doxil (liposomal doxorubicin) | ʻO ka huli ʻana ma o ka hopena EPR | ʻO ka maʻi maʻi ovarian, Multiple myeloma | Liposome |
| Adcetris (brentuximab vedotin) | CD30 | Hodgkin lymphoma, Anaplastic nui cell lymphoma | Hoʻohui lāʻau antibody (ADC) |
| Kadcyla (trastuzumab emtansine) | HE2 | ʻO ka maʻi maʻi umauma HER2 maikaʻi | Hoʻohui lāʻau antibody (ADC) |
Ke kahua o ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa ke ulu wikiwiki nei. E nānā ka noiʻi e hiki mai ana ma:
Hāʻawi ʻia ka lāʻau lapaʻau no ka maʻi kanesa paʻa i ka ʻōlelo hoʻohiki nui no ka hoʻomaikaʻi ʻana i ka mālama ʻana i ka maʻi kanesa a me nā hopena maʻi. Ke hoʻomau nei ka noiʻi, hiki iā mākou ke manaʻo e ʻike ʻoi aku ka maikaʻi a pilikino ka lawe ʻana i ka lāʻau lapaʻau no ka maʻi kanesa puka mai nā hoʻolālā, i ka hopena e alakaʻi i ka mālama maʻi maʻi ʻoi aku ka maikaʻi.